Evidence map›Paper›PMID 19418018›Full record

ArticleClinical and experimental medicine2009

Resistance to activation-induced cell death and elevated FLIPL expression of CD4+ T cells in a polyI:C-induced primary biliary cirrhosis mouse model.

Tingwang Jiang, Zhijun Han, Sunxiao Chen, Chuanyong Wu, Yujie Tang, Cheng Qian, Yan Chen, Ye Zhou, Ye Zhu, Mingli Gu and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Toll-like receptor 3 in liver diseases.Gastroenterology research and practice · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Tingwang JiangDepartment of Laboratory Diagnostics, Changzheng Hospital, Second Military Medical University, 200003, Shanghai, China.
Zhijun Han
Sunxiao Chen
Chuanyong Wu
Yujie Tang
Cheng Qian
Yan Chen
Ye Zhou
Ye Zhu
Mingli Gu
Liang Zhu
Dingkang Yao
Anmei Deng
Renqian Zhong
Second Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary biliary cirrhosis (PBC) is a type of organ-specific autoimmune disease in which immune tolerance is impaired by an unknown mechanism. We established a PBC animal model by injecting C57BL/6 mice with polyI:C to study activation-induced cell death (AICD) in CD4+ T lymphocytes and changes of apoptosis-associated molecules as a first step to understand the immune tolerance of PBC mice. Obvious inflammatory cell infiltration was observed in the portal area of the liver tissues in model mice and antimitochondrial antibodies (AMA) positive rate was 80%. The AICD level in both splenic and hepatic CD4+ T cells in the model group were all lower than those in controls, and in the model group the level for hepatic CD4+ T cells were significantly lower than that for splenic CD4+ T cells. Quantitative PCR revealed that FasL mRNA and TRAIL expression in CD4+ T cells in the model group decreased significantly compared with that in the control group. Western blots revealed that the expression of the anti-apoptotic protein FLIP(L) in the model group increased significantly with the FLIP(L) expression in hepatic CD4+ T cells significantly higher than that in splenic CD4+ T cells. There was a positive linear correlation between the number of infiltrated portal areas and relative expression of FLIP(L) in splenic CD4+ T cells in model group. There were no obvious changes for caspase-8 in either group. These results show that the anti-apoptotic ability of CD4+ T lymphocytes play an important role in immune tolerance in the PBC mouse model, and elevated FLIP(L) expression may enhance this ability. The inhibition of FasL and TRAIL expression may also help enhance this anti-apoptotic ability in CD4+ T lymphocytes and contribute to the aggravation of portal area inflammation.

Indexed as

ApoptosisLymphocyte ActivationAnimalsBlotting, WesternCASP8 and FADD-Like Apoptosis Regulating ProteinCD4-Positive T-LymphocytesDisease Models, AnimalFas Ligand ProteinFemaleInterferon InducersLiver Cirrhosis, BiliaryMiceMice, Inbred C57BLPoly I-CReverse Transcriptase Polymerase Chain ReactionRNA, MessengerCASP8 and FADD-Like Apoptosis Regulating ProteinFas Ligand ProteinFasl protein, mouseInterferon InducersPoly I-CRNA, MessengerTNF-Related Apoptosis-Inducing LigandTnfsf10 protein, mouse

Identifiers

PMID19418018
OpenAlexW1970624241

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.